Pembrolizumab improves survival in locally advanced head and neck cancer
1. Among patients with locally advanced head and neck squamous-cell carcinoma (HNSCC), neoadjuvant and adjuvant pembrolizumab improved event-free survival compared to standard care alone. 2. Pembrolizumab was associated with immune-mediated adverse events, including those of grade 3 or higher. Evidence Rating Level: 1 (Excellent) Study Rundown: Resectable locally advanced HNSCC is a disease with high […]
The post Pembrolizumab improves survival in locally advanced head and neck cancer first appeared on 2 Minute Medicine.Source: 2 Minute Medicine